Pulmonary hypertension in end-stage renal disease

Devasahayam, Joe; Oliver, Tony; Joseph, Valentina; Nambiar, Sudheer; Gunasekaran, Kulothungan

doi:10.1016/j.rmed.2020.105905

Cited by 17 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary artery pressures reduce significantly one year after KTx. Living donor grafts are preferable in KTx recipients with PHT to minimise risk of early graft dysfunction [ 18 , 19 ]. Recipients with PSP greater than 45 mmHg should be assessed by a cardiologist [ 16 ].…”

Section: Preoperative Carementioning

confidence: 99%

Anaesthetic Approach to Enhanced Recovery after Surgery for Kidney Transplantation: A Narrative Review

Jaszczuk

Natarajan

Papalois

2022

JCM

View full text Add to dashboard Cite

Enhanced recovery after surgery (ERAS) protocols are designed to reduce medical complications, the length of hospital stays (LoS), and healthcare costs. ERAS is considered safe and effective for kidney transplant (KTx) surgery. KTx recipients are often frail with multiple comorbidities. As these patients follow an extensive diagnostic pathway preoperatively, the ERAS protocol can ideally be implemented at this stage. Small singular changes in a long perioperative pathway can result in significant positive outcomes. We have investigated the current evidence for an ERAS pathway related to anaesthetic considerations in renal transplant surgery for adult recipients.

show abstract

Section: Preoperative Carementioning

confidence: 99%

Anaesthetic Approach to Enhanced Recovery after Surgery for Kidney Transplantation: A Narrative Review

Jaszczuk

Natarajan

Papalois

2022

JCM

View full text Add to dashboard Cite

show abstract

“…Furthermore, valvular heart disease is up to five times more frequent in ESRD compared to the general population with worse outcomes, even after surgical repair [ 56 ]. Pulmonary hypertension is very common among patients with ESRD and is associated with increased mortality [ 57 ]. In a retrospective analysis of the records of patients assessed with echocardiography for transplantation, severely impaired left ventricular function, pulmonary hypertension and/or right ventricular dysfunction and RWMA were independently associated with all-cause mortality over a mean follow-up of 4.2 years.…”

Section: Non-coronary Cardiac Diseasementioning

confidence: 99%

Cardiac Imaging and Management of Cardiac Disease in Asymptomatic Renal Transplant Candidates: A Current Update

et al. 2022

View full text Add to dashboard Cite

Given the high cardiovascular risk accompanying end-stage kidney disease, it would be of paramount importance for the clinical nephrologist to know which screening method(s) identify high-risk patients and whether screening asymptomatic transplant candidates effectively reduces cardiovascular risk in the perioperative setting as well as in the longer term. Within this review, key studies concerning the above questions are reported and critically analyzed. The lack of unified screening criteria and of a prognostically sufficient screening cardiovascular effect for renal transplant candidates sets the foundation for a personalized patient approach in the near future and highlights the need for well-designed studies to produce robust evidence which will address the above questions.

show abstract

“…Furthermore, PH is a risk factor for mortality in ESRD [6]. In hemodialysis (HD) patients, PH is a separate predictor of cardiovascular morbidity and all-cause mortality [7][8][9][10]. The mortality rate is four times greater in HD patients with PH than in those without PH [7].…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Nomogram for Predicting All-Cause Mortality in Patients with Hemodialysis Having Pulmonary Hypertension

Wu,

Huan,

et al. 2023

Cardiorenal Med

View full text Add to dashboard Cite

Introduction: Patients with end-stage renal disease receiving hemodialysis (HD) have a high morbidity and mortality rate associated with pulmonary hypertension (PH). A nomogram was developed to predict all-cause mortality in HD patients with PH. In this study, we aimed to validate the usefulness of this nomogram. Methods: A total of 274 HD patients with PH were hospitalized at the Affiliated Hospital of Xuzhou Medical University between January 2014 and June 2019 and followed up for 3 years. Echocardiography detected PH when the peak tricuspid regurgitation velocity (TRV) was more than 2.8 m/s. To evaluate the all-cause mortality for long-term HD patients with PH, Cox regression analysis was performed to determine the factors of mortality that were included in the prediction model. Next, the area under the receiver-operating characteristic curve (AUC-ROC) was used to assess the predictive power of the model. Calibration plots and decision curve analysis (DCA) were used to assess the accuracy of the prediction results and the clinical utility of the model. Results: The all-cause mortality rate was 29.20% throughout the follow-up period. The nomogram comprised six commonly available predictors: age, diabetes mellitus, cardiovascular disease, hemoglobin, left ventricular ejection fraction, and TRV. The 1-year, 2-year, and 3-year AUC-ROC values were 0.842, 0.800, and 0.781, respectively. The calibration curves revealed excellent agreement with the nomogram, while the DCA demonstrated favorable clinical practicability. Conclusion: The first developed nomogram for predicting all-cause mortality in HD patients with PH could guide clinical decision-making and intervention planning.

show abstract

Pulmonary hypertension in end-stage renal disease

Cited by 17 publications

References 28 publications

Anaesthetic Approach to Enhanced Recovery after Surgery for Kidney Transplantation: A Narrative Review

Anaesthetic Approach to Enhanced Recovery after Surgery for Kidney Transplantation: A Narrative Review

Cardiac Imaging and Management of Cardiac Disease in Asymptomatic Renal Transplant Candidates: A Current Update

Development and Validation of a Nomogram for Predicting All-Cause Mortality in Patients with Hemodialysis Having Pulmonary Hypertension

Contact Info

Product

Resources

About